CHO Pharma, Inc. (TPEX:6586)
Taiwan · Delayed Price · Currency is TWD 66.80
+2.00 (3.09%)
May 29, 2026, 1:55 PM CST
CHO Pharma Revenue
In the year 2025, CHO Pharma had annual revenue of 1.43M TWD, down -60.03%. CHO Pharma had revenue of 719.00K in the half year ending December 31, 2025.
Revenue
1.43M
Revenue Growth
-60.03%
P/S Ratio
10,109.79
Revenue / Employee
n/a
Employees
47
Market Cap
14.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.43M | -2.15M | -60.03% |
| Dec 31, 2024 | 3.58M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 60.00K | -3.51M | -98.32% |
| Dec 31, 2021 | 3.57M | 3.43M | 2,486.96% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sunmax Biotechnology | 2.04B |
| EirGenix | 1.13B |
| Ever Supreme Bio Technology | 1.03B |
| Medigen Vaccine Biologics | 603.68M |
| TaiMed Biologics | 601.19M |
| Tanvex BioPharma | 483.94M |
| Polaris Group | 69.27M |
| Gongwin Biopharm Holdings | 38.28M |